Swedish researchers found that rising levels of cardiac troponin measured by a high-sensitivity assay were associated with increased adjusted hazard ratios for all-cause, cardiovascular- and noncardiovascular-related mortality, heart failure and myocardial infarction, according to a study. During heart failure, a small but continuous release of cTnT from the myocardium is an indication that "chronic troponin release may be mediated by functional and structural heart diseases rather than by ischemic heart disease," researchers wrote.
A study of brain tissue from people with either schizophrenia, bipolar disorder, autism, depression or alcoholism suggests there are some similar gene expression patterns among those conditions. "This work shows that using molecular features we might be able to get a good picture of these disorders, and develop targeted therapies," said Daniel Geschwind, an author of the study published in Science.
Two studies, one in the journal Nature Medicine and the other in the journal Nature Communications, provided additional input on the effect of the Zika virus on infants. The first explored how Zika can affect the brains of infants with normal-sized heads, and the second found hints that genetics may be a factor in how susceptible some infants are to Zika-related birth defects.
The SensAheart device was developed in Israel to detect heart attacks experienced by patients as recently as an hour prior using blood samples taken by finger prick, providing results within about five minutes. The device, approximately the size of a USB stick, is available in Israel and Europe, and its inventor, Novamed founder and CEO Emil Katz, is working on bringing the device to the US market.
The White House's 2019 budget request will include provisions allowing point-of-sale drug rebates under Medicare Part D and capping subscribers' out-of-pocket expenses, according to HHS Secretary Alex Azar. Copays for some generic drugs would also be eliminated for low-income subscribers, and drugs now covered under Part B would be covered by Part D plans, Azar said.
Vela Diagnostics obtained clearance from the FDA for its Sentosa SA201 HSV-1/2 PCR test, a herpes simplex virus assay that spots viral DNA in skin lesions from oral or anal sites in symptomatic individuals. The test operates on 96-well plates on the Sentosa SX101 instrument after nucleic acid extraction with the Sentosa SX Virus Total Nucleic Acid Kit.
Qiagen secured approval from Japan's Ministry of Health, Labor and Welfare for its QuantiFeron-TB Gold Plus or QFT-Plus, the fourth generation of its QuantiFeron-TB technology, for use as an in vitro diagnostic in tuberculosis infection detection. QFT-Plus streamlines screening in large-scale tuberculosis control programs through the combination of a flexible blood collection workflow and CD4+/CD8+ design for comprehensive immune response detection.
A round of seed financing brought in over $1.5 million for South Bend, Ind.-based AgenDx Biosciences, an early-stage company that makes molecular diagnostics technology for pancreatic cancer treatment. The money will be used "to achieve additional critical engineering and clinical milestones," said company CEO Kevin Connors.
Denmark-based in vitro diagnostics company BioPorto signed an agreement with Roche Holding to globally distribute its CE-marked neutrophil gelatinase-associated lipocalin test for use on Cobas c 502 and Cobas c 501 analyzers to diagnose acute kidney injury; terms were undisclosed. Clinical studies are being conducted by BioPorto as it expects to receive FDA approval for the test later this year.
North American Clinical Chemist Association (NACCCA) is now accepting applications for the NACCCA Research Grant sponsored by the Dream Diagnostics Medicine (DDM). This grant is for research in a variety of areas of the clinical laboratory science, including diagnostics and detection technologies, medical devices, genomics/proteomics/metabolomics and emerging biomarkers.
Have you ever been faced with a challenging conversation in the workplace? Join AACC and LabLeaders for this prerecorded webinar to learn a simple three-step process for dealing with the most difficult, and often most important, conversations.